Ensign Peak Advisors
KROS icon

Ensign Peak Advisors’s Keros Therapeutics KROS Stock Holding History

Ensign Peak Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-340
Closed -$5.38K – 1708
2024
Q4 		$5.38K Sell
340
-71,400
-100% -$3.71M ﹤0.01% 1707
2024
Q3 		$4.17M Hold
71,740
– – 0.01% 691
2024
Q2 		$3.28M Hold
71,740
– – 0.01% 746
2024
Q1 		$4.75M Buy
+71,740
New +$4.25M 0.01% 642
2022
Q4 		– Sell
-2,380
Closed -$90K – 2012
2022
Q3 		$90K Hold
2,380
– – ﹤0.01% 2118
2022
Q2 		$66K Hold
2,380
– – ﹤0.01% 2036
2022
Q1 		$129K Hold
2,380
– – ﹤0.01% 1983
2021
Q4 		$139K Buy
+2,380
New +$119K ﹤0.01% 2005

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ensign Peak Advisors's KROS Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 340 shares — an estimated $5.38K sold.

Ensign Peak Advisors first reported a position in KROS in Q4 2021 and held it in 8 quarters. The position peaked at $4.75M in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 340 Keros Therapeutics shares in Q1 2025, an estimated $5.38K.
  • Ensign Peak Advisors first reported a position in Keros Therapeutics in Q4 2021 and held it in 8 quarters.
  • Ensign Peak Advisors's Keros Therapeutics position peaked at $4.75M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.